(NASDAQ: ETNB) 89bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.89%.
89bio's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast ETNB's revenue for 2026 to be $3,564,930,297, with the lowest ETNB revenue forecast at $801,738,632, and the highest ETNB revenue forecast at $5,063,556,670. On average, 3 Wall Street analysts forecast ETNB's revenue for 2027 to be $24,102,572,112, with the lowest ETNB revenue forecast at $6,660,679,334, and the highest ETNB revenue forecast at $42,289,859,406.
In 2028, ETNB is forecast to generate $61,959,780,665 in revenue, with the lowest revenue forecast at $20,744,589,937 and the highest revenue forecast at $108,038,781,819.